[Hypertension, HIV infection, and highly active antiretroviral therapy]

Enferm Infecc Microbiol Clin. 2010 Jan;28(1):32-7. doi: 10.1016/j.eimc.2008.07.005. Epub 2009 May 1.
[Article in Spanish]

Abstract

The decline in mortality resulting from the use of highly active antiretroviral therapy (HAART) has been accompanied by an increase in metabolic complications that produce accelerated atherosclerosis. Hypertension is one of the most important cardiovascular risk factors. Little is known about the impact of HAART on blood pressure, and it is uncertain whether chronic HIV infection or HAART have a role in the development of hypertension. In this study, the research on the relationships between hypertension and HIV infection published to date is reviewed. Antiretroviral therapy appears to have a modest impact on blood pressure and to be partially mediated by the metabolic changes occurring with this treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / pharmacology
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Atherosclerosis / etiology
  • Atherosclerosis / prevention & control
  • Blood Pressure / drug effects
  • Cohort Studies
  • Dyslipidemias / chemically induced
  • Dyslipidemias / complications
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / pharmacology
  • Humans
  • Hypertension / chemically induced
  • Hypertension / epidemiology
  • Hypertension / etiology*
  • Hypertension / prevention & control
  • Insulin Resistance
  • Kidney Diseases / chemically induced
  • Kidney Diseases / etiology
  • Kidney Diseases / physiopathology
  • Male
  • Metabolic Syndrome / chemically induced
  • Middle Aged
  • Models, Biological
  • Multicenter Studies as Topic / statistics & numerical data
  • Myocardial Ischemia / epidemiology
  • Myocardial Ischemia / etiology
  • Prevalence

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors